Results 171 to 180 of about 6,869,290 (307)

ACELG_Local_Representation_in_Australia.pdf

, 2013
This paper outlines the outcomes of interviews with various councillors and senior staff to gauge their experiences, opinions and perspectives on the governance framework set out in the Victorian Local Government Act 1989.
Bligh Grant, Su Fei Tan
core  

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Integrating ESG indicators into public health governance as a policy innovation for institutional accountability: a scoping review. [PDF]

Public Health Rev
Catalfo P, Virgillito D, Messina G, Ledda C.   +3 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

A framework for population health observatory from a global perspective: proposed preliminary maturity model and key performance indicators. [PDF]

Front Public Health
AlEissa MM, Alomary SA, Assiri AM.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Developing an inclusive research (methods) strategy for the Manchester Biomedical Research Centre and Clinical Research Facility. [PDF]

PLoS One
Coleman A, Medahunsi S, Elliott J, Mould J, Thomas A, Varga E, Verma A.   +6 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Urban transport experimentation: a network or hybrid governance process?

Innovative sustainable transport policies are often tested through experiments or pilots. This chapter focuses on how urban transport experimentation is governed, in today’s context where collaboration and partnerships beyond government are often posited as the key to policy innovation.
openaire   +2 more sources

Editorial: Greening urban spaces and human health, volume III. [PDF]

Front Public Health
Akpınar A, Li Y, Li D.
europepmc   +1 more source